Studie - Polycystic Ovarian Syndrome – Pipeline Review, H1 2012
Global Markets Direct
2 / 2012
48 Seiten
| Typ: | Studie |
| Sprache: | Englisch |
| Regionen: | Europa, Asien / Pazifik, Mittlerer Osten / Afrika, Nordamerika / USA, Australien, Mittel- / Südamerika |
| Verfügbarkeit: | verfügbar |
Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:
Polycystic Ovarian Syndrome — Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Polycystic Ovarian Syndrome - Pipeline Review, H1 2012', provides an overview of the Polycystic Ovarian Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Ovarian Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome. 'Polycystic Ovarian Syndrome - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Polycystic Ovarian Syndrome.
- A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Polycystic Ovarian Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Polycystic Ovarian Syndrome - Pipeline Review, H1 2012', provides an overview of the Polycystic Ovarian Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Ovarian Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome. 'Polycystic Ovarian Syndrome - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Polycystic Ovarian Syndrome.
- A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Polycystic Ovarian Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Polycystic Ovarian Syndrome Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Polycystic Ovarian Syndrome 8
Polycystic Ovarian Syndrome Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Polycystic Ovarian Syndrome Therapeutics — Products under Investigation by Universities/Institutes 14
Polycystic Ovarian Syndrome — Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Combination Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
OCP - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Metformin - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Raloxifene - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Letrozole - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Human Chorionic Gonadotropin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Human Chorionic Gonadotropin + Clomiphene Citrate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Metformin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Metformin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Metformin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Aldactone - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
D-chiro-inositol - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Simvastatin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Dexamethasone + Recombinant hCG - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 37
Metformin + Clomiphene - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Tamoxifen + Clomiphene - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Flutamide + Metformin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Clomiphene Citrate + Dexamethasone - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Medroxyprogesterone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Metformin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Aspirin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Polycystic Ovarian Syndrome Therapeutics — Drug Profile Updates 45
Polycystic Ovarian Syndrome Therapeutics - Dormant Products 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 48
Contact Us 48
Disclaimer 48
List of Tables
Number of Products Under Development for Polycystic Ovarian Syndrome, H1 2012 8
Products under Development for Polycystic Ovarian Syndrome — Comparative Analysis, H1 2012 9
Number of Products under Investigation by Universities/Institutes, H1 2012 11
Comparative Analysis by Late Stage Development, H1 2012 12
Comparative Analysis by Mid Clinical Stage Development, H1 2012 13
Products under Investigation by Universities/Institutes, H1 2012 14
Assessment by Monotherapy Products, H1 2012 15
Assessment by Combination Products, H1 2012 16
Assessment by Stage and Route of Administration, H1 2012 18
Assessment by Stage and Molecule Type, H1 2012 20
Polycystic Ovarian Syndrome Therapeutics — Drug Profile Updates 45
Polycystic Ovarian Syndrome Therapeutics — Dormant Products 46
List of Figures
Number of Products under Development for Polycystic Ovarian Syndrome, H1 2012 8
Products under Development for Polycystic Ovarian Syndrome — Comparative Analysis, H1 2012 9
Products under Investigation by Universities/Institutes, H1 2012 10
Late Stage Products, H1 2012 12
Mid Clinical Stage Products, H1 2012 13
Assessment by Monotherapy Products, H1 2012 15
Assessment by Combination Products, H1 2012 16
Assessment by Route of Administration, H1 2012 17
Assessment by Stage and Route of Administration, H1 2012 18
Assessment by Molecule Type, H1 2012 19
Assessment by Stage and Molecule Type, H1 2012 20
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Polycystic Ovarian Syndrome Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Polycystic Ovarian Syndrome 8
Polycystic Ovarian Syndrome Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Polycystic Ovarian Syndrome Therapeutics — Products under Investigation by Universities/Institutes 14
Polycystic Ovarian Syndrome — Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Combination Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
OCP - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Metformin - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Raloxifene - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Letrozole - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Human Chorionic Gonadotropin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Human Chorionic Gonadotropin + Clomiphene Citrate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Metformin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Metformin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Metformin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Aldactone - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
D-chiro-inositol - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Simvastatin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Dexamethasone + Recombinant hCG - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 37
Metformin + Clomiphene - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Tamoxifen + Clomiphene - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Flutamide + Metformin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Clomiphene Citrate + Dexamethasone - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Medroxyprogesterone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Metformin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Aspirin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Polycystic Ovarian Syndrome Therapeutics — Drug Profile Updates 45
Polycystic Ovarian Syndrome Therapeutics - Dormant Products 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 48
Contact Us 48
Disclaimer 48
List of Tables
Number of Products Under Development for Polycystic Ovarian Syndrome, H1 2012 8
Products under Development for Polycystic Ovarian Syndrome — Comparative Analysis, H1 2012 9
Number of Products under Investigation by Universities/Institutes, H1 2012 11
Comparative Analysis by Late Stage Development, H1 2012 12
Comparative Analysis by Mid Clinical Stage Development, H1 2012 13
Products under Investigation by Universities/Institutes, H1 2012 14
Assessment by Monotherapy Products, H1 2012 15
Assessment by Combination Products, H1 2012 16
Assessment by Stage and Route of Administration, H1 2012 18
Assessment by Stage and Molecule Type, H1 2012 20
Polycystic Ovarian Syndrome Therapeutics — Drug Profile Updates 45
Polycystic Ovarian Syndrome Therapeutics — Dormant Products 46
List of Figures
Number of Products under Development for Polycystic Ovarian Syndrome, H1 2012 8
Products under Development for Polycystic Ovarian Syndrome — Comparative Analysis, H1 2012 9
Products under Investigation by Universities/Institutes, H1 2012 10
Late Stage Products, H1 2012 12
Mid Clinical Stage Products, H1 2012 13
Assessment by Monotherapy Products, H1 2012 15
Assessment by Combination Products, H1 2012 16
Assessment by Route of Administration, H1 2012 17
Assessment by Stage and Route of Administration, H1 2012 18
Assessment by Molecule Type, H1 2012 19
Assessment by Stage and Molecule Type, H1 2012 20
- Acute Inflammation – Pipeline Review, H1 2013
- Ovarian Disease – Pipeline Review, H1 2013
- Premenstrual Syndrome – Pipeline Review, H1 2013
- Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2013
- Cervical Dysplasia – Pipeline Review, H1 2013
- EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
- Female Sexual Dysfunction – Pipeline Review, H1 2013
- Menopausal Disorders – Pipeline Review, H1 2013
- Menopausal Hot Flashes – Pipeline Review, H1 2013
- Uterine Fibroids – Pipeline Review, H1 2013
- Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2013
- Contraceptives – Pipeline Review, H1 2013
- Dysmenorrhea – Pipeline Review, H1 2013
- Endometriosis – Pipeline Review, H1 2013
- Women Infertility – Pipeline Review, H1 2013
- Premature Labor (Tocolysis) – Pipeline Review, H2 2012
- Vasomotor Symptoms of Menopause – Pipeline Review, H2 2012
- Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen
- Premature Ovarian Failure – Pipeline Review, H2 2012
- Premenstrual Syndrome – Pipeline Review, H2 2012
*Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.
Für Sie protokollierte Studien / Marktanalysen:
zuletzt angesehene Studien:
Seite drucken
Seite empfehlen
Home | Werbung | Über marktforschung.de | AGB | Impressum | Sitemap | Suche © 2006 bis 2013 Alle Rechte bei marktforschung.de - Studie - Polycystic Ovarian Syndrome – Pipeline Review, H1 2012 - Marktdaten / Marktanalysen bei marktforschung.de